Adma Biologics reported $67.23M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.


Gross Profit On Sales Change Date
Adma Biologics USD 67.23M 3.9M Jun/2025
Alnylam Pharmaceuticals USD 630.74M 107.59M Jun/2025
Dynavax Technologies USD 78.57M 24.17M Jun/2025
Takeda JPY 722.01B 50.69B Jun/2025